Phase 2 Neuroendocrine Tumor Clinical Trials
45 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 45 trials
Recruiting
Phase 2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Unresectable Digestive System Neuroendocrine Tumor G1Unresectable Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)100 enrolled36 locationsNCT05773274
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2Phase 3
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755
Recruiting
Phase 1Phase 2
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Hepatocellular CarcinomaNeuroendocrine TumorsGastrointestinal Cancer Metastatic
Teclison Ltd.25 enrolled2 locationsNCT02174549
Recruiting
Phase 2
Agnostic Therapy in Rare Solid Tumors
Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan49 enrolled11 locationsNCT05048901
Recruiting
Phase 1Phase 2
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 2
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting
Phase 2
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Carcinoma, Small CellNeuroendocrine TumorsGastrointestinal Stromal Tumors+11 more
Centre Oscar Lambret88 enrolled3 locationsNCT05500391
Recruiting
Phase 2
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco29 enrolled1 locationNCT05746208
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252
Recruiting
Phase 2
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Gynecologic CancerNeuroendocrine Tumors
University of Utah86 enrolled1 locationNCT07151391